These findings shed light on the pathogenic mechanism of ATP13A3 genetic defects leading to a loss of function in PAH and provide new insight into a potential role for polyamine dysregulation in the pathobiology of PAH. Here, ATP13A3 is linked to pulmonary arterial hypertension.